[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"progression-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:progression-disease":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100539617","advanced-radiotherapy-art-in-gynecological-cancer-patients-gyn-art-100539617",false,"NCT06306170","Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)","Efficacy of Advanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART)","GYN-ART","Inclusion Criteria:\n\n* gynecologic cancer patients\n* \\>18 years old\n* treated with advanced radiotherapy techniques (IGRT, IMRT, SBRT)\n\nExclusion Criteria:\n\n* other tumors\n* \\> 90 years old","FEMALE","18 Years","90 Years",{"count":21,"type":22},1000,"ESTIMATED","OBSERVATIONAL","This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- will be included and toxicity and outcomes analyzed.",[26,27,28,29,30,31],"Gynecologic Cancer","Radiotherapy Side Effect","Radiotherapy; Complications","Survivorship","Progression, Disease","Progression, Clinical",[26,33,34,35,36,37],"Image Guided Radiotherapy","PET\u002FCT","Intensity Modulated Radiotherapy","Stereotactic Body Radiotherapy","Oligometastases","RECRUITING","2025-04-19",{"date":41,"type":42},"2025-04-22","ACTUAL",{"date":44,"type":42},"2024-02-15",{"date":46,"type":22},"2029-02-15",{"name":48,"class":49},"IRCCS San Raffaele","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":61,"conditions":62,"keywords":79,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":50},"100529161","study-on-the-quality-of-life-and-pathological-state-in-patients-who-underwent-radical-cystectomy-100529161","NCT06170177","Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy","Bladder Archive: Observational Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy","Inclusion Criteria:\n\n* subjects underwent radical cystectomy\n* \\> 18 years old\n* Ability to read and sign the informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Inability to read and sign the informed consent","ALL",{"count":60,"type":22},4000,"Observational study on the quality of life and pathological state of patients underwent radical cystectomy.",[63,64,65,66,67,68,69,70,71,72,73,74,75,30,76,77,78],"Muscle-Invasive Bladder Carcinoma","Muscle Invasive Bladder Urothelial Carcinoma","Bladder Cancer TNM Staging","Bladder Cancer Stage IIa","Bladder Cancer Stage IIb","Bladder Cancer Stage IV","Bladder Leiomyosarcoma","Bladder Cancer","Bladder Cancer Stage II","Bladder Cancer Stage IIIa","Bladder Cancer Stage IIIb","Bladder Cancer Stage IIIc","Bladder Urothelial Carcinoma","Urinary Diversion","Neobladder","Radical Cystectomy",[78],"2023-12-06",{"date":82,"type":42},"2023-12-14",{"date":84,"type":42},"2013-02-04",{"date":86,"type":22},"2063-02",{"name":48,"class":49},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":58,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":50},"100490216","phase-4-the-effects-of-using-different-anesthetics-on-the-prognosis-of-primary-lung-tumors-and-its-mechanism-of-action-100490216","NCT05663242","The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and Its Mechanism of Action","To Compare the Effects of Intraoperative Use of Intravenous Anesthetics Propofol and Inhaled Anesthetics Sevoflurane on the Prognosis of Patients Undergoing Surgery for Primary Lung Tumors and the Investigation of Its Mechanism of Action.","Inclusion Criteria:\n\n* eighteen to eighty-year-old\n* ASA class I-III patients\n* Received elective thoracic surgery for primary lung tumors under general anesthesia\n\nExclusion Criteria:\n\n* mental disorder\n* poor liver function\n* pregnant or lactating women\n* morbidly obese\n* allergy to any of the drugs used in this study\n* recurrent tumor or repeat surgery\n* biopsy cases\n* incomplete outcome-data\n* palliative treatment after surgery\n* simultaneous treatment of other malignancies\n* emergency surgery\n* presence of other malignant tumors\n* combined propofol and inhalation anesthesia or other anesthetics, such as ketamine or dexmedetomidine\n* diagnosed as benign lung tumor, or other metastatic lung tumor","20 Years","80 Years",{"count":98,"type":22},300,"INTERVENTIONAL",[101],"PHASE4","This is a two-arm, parallel-group randomized clinical trial. Routine perioperative care would be performed in volunteers with primary early lung cancer. The study will enroll approximately 300 volunteers to compare the progression-free or overall survival in patients undergoing video-assisted thoracoscopic surgery (VATS) for primary lung tumors between propofol and sevoflurane for the maintenance of anesthesia.",[104,30,105],"Lung Cancer","Anesthesia",[107,108,104,109],"Propofol","Sevoflurane","VATS","2023-05-26",{"date":112,"type":42},"2023-05-30",{"date":114,"type":42},"2022-12-27",{"date":116,"type":22},"2026-11-30",{"name":118,"class":49},"Kaohsiung Medical University Chung-Ho Memorial Hospital"]